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Beginning in the late 1970's, physicians in New York and
San Francisco reported the increasing occurrence of a rare type
of cancer (Kaposi's sarcoma), and a variety of infections
including pneumocystis pneumonia among previously healthy
young homosexual males (Brandt, 1993:547). The physicians
were baffled by these mysterious deaths because these illnesses
are usually controlled by the body's defenses (Shubert,
1992: 1). Due to the unusual character of these diseases,
epidemiologists began to search for the characteristics that
might link the cases (Brandt, 1993:547). This research
eventually led to the description of Acquired Immunodeficiency
Syndrome (AIDS) in 1981. Evidence indicates that the causal
virus had been spreading undetected in numerous populations
during the 1970's (Brandt, 1993:547). Early studies showed
that homosexual men, recipients of blood transfusions or
blood products (often haemophiliacs), and intravenous drug
users were at greatest risk for acquiring the disease (Brandt,
1993:547). For this reason, researchers focused on a common
infectious agent that could be transmitted sexually or through
blood (Brandt, 1993:547). In 1983, Frenchman Luc
Montagnier and American Robert Gallo independently
identified a previously undescribed human retrovirus (Brandt,
1993:547). This new virus was named Human
Immunodeficiency Virus (HIV).
Tests to detect antiviral antibodies, specific for HIV were
first devised in 1984 (Brandt, 1993 :547). These tests do not
detect the virus directly, instead they measure the high levels
of antibodies which are produced upon infection (Brandt,
1993:547).
This paper is about mv, the virus which is transmitted
between humans, and may manifest into AIDS. It will discuss
the biology and life cycle of HIV, the evolution of HIV,
transmission of HIV, how AIDS can affect human population
dynamics, and current research on the treatment of AIDS.
Like all viruses, HIV is an intracellular parasite. The virus
particle is inactive and therefore cannot reproduce or do any
damage until it enters a host cell (Weber and Weiss, 1988:75).
HIV is an RNA (ribonucleic acid) human retrovirus, which
means that it reverses the normal flow of genetic information
by using an enzyme, reverse transcriptase (Dalgleish,
1990: 122). In cells, the genetic material is DNA
(deoxyribonucleic acid). When genes are expressed, the DNA is
first transcribed into messenger RNA (mRNA), which then
serves as a template for translation to proteins (Haseltine and
Wong-Staal, 1988:14). The genes of a retrovirus are encoded
in RNA. Before they can be expressed, the RNA must be
converted into DNA (Haseltine and Wong-Staal, 1988:14).
Only after this occurs are the viral genes transcribed into
mRNA and translated into proteins (Haseltine and Wong-
Staal, 1988:14). In addition to the three genes which code for
the proteins of the core and envelope, the HIV genome also
contains six other genes which regulate the production of viral
proteins (Haseltine and Wong-Staal, 1988:15).
The first half of the HIV life cycle begins when a virus
particle binds to a component of the host cell's membrane
(Weber and Weiss, 1988:75). HIV binds to the CD4 antigen,
which is found primarily on cells of the immune system called
T4 cells (Weber and Weiss, 1988:75). The T4 cells are small
resting lymphocytes, which become activated in response to an
antigen (Wain-Hobson, 1994:186). Since its initial discovery
on T4 cells, CD4 antigen has also been found on macrophages
(scavenger cells in the bloodstream, which prevent infection),
skin cells, and cells of various organs (Weber and Weiss,
1988:80). HIV infection is characterized by the destruction of
the T4 cells, thereby causing a deterioration of the immune
system (Weber and Weiss, 1988:75).
Binding takes place when a CD4 antigen interacts with a
viral protein (gp120) located on the outside of the viral
membrane (Weber and Weiss, 1988:75). This binding is the
first step of viral entry into the cell (Weber and Weiss,
1988:77). The viral membrane fuses with the cell membrane
and injects the core of the virus into the target cell (Weber and
Weiss, 1988:77).
The core contains two identical strands of RNA as well as
enzymes and structural proteins (Haseltine and Wong-Staal,
1988:14). Reverse transcriptase is responsible for converting
the viral genetic information into single stranded DNA
(Haseltine and Wong-Staal, 1988:14). A second enzyme
destroys the original RNA, and the polymerase makes a second
DNA strand, using the first one as a template (Haseltine and
Wong-Staal, 1988:14). The viral genetic information, now as
double-stranded DNA, migrates to the cell nucleus, where a
third viral enzyme, called an integrase, splices the HIV genetic
information into the host cell's DNA (Haseltine and Wong-
Staal, 1988:14). Once there, the viral DNA (also known as the
provirus) will be replicated together with the cell's own genes
every time the cell divides (Haseltine and Wong-Staal,
1988:14). Once established in the individual, the incorporated
viral genome is a permanent component of the hosts' genome.
The second half of the viral life cycle, which involves the
production of new virus particles, takes place randomly and
may be delayed for up to 10 years. Only certain infected cells
are triggered to produce mature viral particles. The symptoms
of this part of the life cycle is what is known as "full blown
AIDS" (Haseltine and Wong-Staal, 1988:14).
When individuals are first infected with HIV they generate
a strong immune response to the virus (Weber and Weiss,
1988:84). They produce antibodies to all the viral proteins and
their immune system activates the various types of killer and
scavenger cells that are part of any normal immune response
(Weber and Weiss, 1988:84). However, once infection has
occurred these immune responses do not stop the progress of
the disease, due to the lack of active T4 cells which would
normally prevent infection. Thus the HIV afflicted individual
is now susceptible to attack by any other pathogen (viral,
Charno: HIV: Its Development Within the Human Population
Produced by The Berkeley Electronic Press, 1995
bacterial, or fungal) and unlike a healthy individual, is unable
to defend him or herself.
HIV is transmitted only through the direct exchange of
blood, semen or vaginal secretions (Shubert, 1992:7). To date
four routes of transmission have been identified: (1)
unprotected sexual contact, (2) un-screened transfusions or
infusions of blood or blood by-products, (3) sharing of
intravenous needles, (4) congenital or perinatal transmission
from a woman to her fetus or newborn (Shubert, 1992:7).
Infected blood poses a threat only if it comes in contact with
an open wound or when there is an inoculation (Shubert,
1992:7).
Brandt (1993:547) has identified three epidemiological
patterns of HIV transmission, which follow geographic
boundaries. Pattern I includes North America, Western Europe,
Australia, New Zealand and many urban centres in Latin
America. In these highly developed areas, transmission has
been predominantly among homosexual and bisexual males.
Since the introduction of widespread blood screening,
transmission via blood now occurs principally among
intravenous drug users who share syringes. Although there is
no evidence of widespread infection among the heterosexual
populations in these countries, heterosexual transmission of
the virus from those infected via intravenous drug use has
increased.
In pattern II countries, which consist of sub-Saharan
Africa and Latin America, transmission of HIV occurs through
heterosexual contact. In some urban areas, up to 25 percent of
sexually active adults are infected. Transfusion is a dominant
form of transmission because universal screening of blood is
not routine in these countries.
Pattern ill countries include North Africa, the Middle East,
Eastern Europe, Asia, and the Pacific. In these locales, HIV
was not present until the mid 1980's. Therefore, infection has
been the result of contact with infected individuals from pattern
I and II countries, or importation of infected blood.
In the early to mid 1980's HIV transmission to
haemophiliacs was first noted (Anderson and Gazzard,
1990:91). This mode of transmission has since been reduced,
but not eliminated, by the heating of plasma to 56cC, and the
screening of donor plasma (Anderson and Gazzard, 1990:91).
The number of individuals affected in Pattern I, II, and III
countries has been steadily increasing. It has been suggested
that by the year 2000 the number of mv infected individuals
will be between 40 and 100 million (Wain-Hobson,
1994:203).
mv, which causes AIDS in humans, is an example of
"fast-forward" evolution (Myers and Korber, 1994:211).
Because of their high error rate during replication, RNA
viruses show high host diversity and a rate of evolution about
a million times faster than that of DNA organisms (Penny,
1988:494).
Researchers in 1984, while examining the origins of HIV ,
began to look for similar viruses in non-human primates
(Essex and Kanki, 1988:27). At this same time, veterinary
pathologists in primate research centres reported symptoms
similar to AIDS in captive Asian macaques (Essex and Kanki,
1988:30). HIV related antibodies in the macaques were isolated
and the causal virus was named Simian Immunodeficiency
Virus (SIV) (Essex and Kanki, 1988:30). There is now strong
evidence suggesting that the HIVs and SIVs have evolved from
an unknown precursor within the highly diverse family of
retroviruses (Myers and Korber, 1994:212). The world-wide
prevalence of these retroviruses suggests that they are old, but
their exact age and time of divergence has yet to be determined
(Myers and Korber, 1994:212).
Like humans infected with HIV, Asian macaques infected
with SIV suffer a decrease in T4 cells, and the animals die of
infections very similar to those seen in human AIDS patients
(Essex and Kanki, 1988:30). Further studies revealed that
Asian macaques in the wild were not infected with SIV, unlike
those in captivity (Essex and Kanki, 1988:30). The research
then focused on Africa for a possible link in African primates.
Blood samples from chimpanzees, baboons, and African green
monkeys were analyzed for antibodies that reacted to the SIV
virus from Asian macaques (Essex and Kanki, 1988:30). The
results found no evidence of SIV infection in the chimpanzees
or baboons. However, over 50 percent of the wild African
green monkeys studied showed evidence of an SIV infection,
but exhibited no symptoms of AIDS (Essex and Kanki,
1988:30).
The fact that SIV appeared harmless in African green
monkeys but lethal to captive Asian macaques, indicated that
some SIV strains might have evolved toward co-existence
with their monkey hosts (Essex and Kanki, 1988:32). Most
retroviruses tend to co-exist with their host species in a way
that allows both to survive, and thus have become non-
pathogenic (Essex and Kanki, 1988:32). It appears that HIV
and SIV may be most pathogenic when they first afflict a new
species, thus selecting for the survival of the virus and the
host strains (Essex and Kanki, 1988:32).
The primate research done in the early 1980's led to the
discovery of a new retrovirus which was infecting people in
West Africa (Essex and Kanki, 1988:34). This new West
African retrovirus was somewhat similar to the mv virus in
Central Africa, Europe, and the U.S. However, it was found to
be more closely related to SIV (Anderson and Gazzard,
1990:88). This new discovery led to the original AIDS virus
being named HIV -1, and the West African virus being named
HIV-2 (Essex and Kanki, 1988:34). The fact that HIV-2 is
more similar to SIV than it is to HIV-l, indicates that primate
and human viruses share evolutionary roots and that there may
have been inter-species infection (Essex and Kanki, 1988:34).
Attempts to reconstruct the evolutionary tr!(e for HIV has
been difficult for two reasons: (1) the high variation in
nucleotide sequence among HIV isolates caused by rapid
mutations, (2) there is only a sparse "fossil record" for HIV
and limited historical and epidemiological data (Smith et aI.,
1988:573). Despite this, Smith et aI. (1988) compared the
envelope gene sequences from both old and new HIV isolates
and calculated that HIV-1 and HIV -2 split off from a common
ancestor as recently as 40 years ago. However Sharp and Li
(1988:315) dispute the validity of the 40 year split. Rather,
they used the conserved DNA sequence of the polymerase gene
to estimate that the divergence of HIV-l, from HIV-2, and
SIV occurred between 140 and 160 years ago. Furthermore,
because HIV-l and HIV-2 seem to have evolved at similar
rates, Sharp and Li (1988) estimated that mV-2 and SIV
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diverged only about 30 years ago. They argue that since all
three viruses are from a common ancestor, all three were
pathogenic. Because HIV-l and HIV-2 cause AIDS whereas
SIV does not, SIV probably lost its pathogenicity after the
divergence. Conversely, if the three viruses were originally
non-pathogenic, then HIV-l and HIV-2 must have acquired
their pathogenicity independently after divergence (Sharp and
Li, 1988:315). This would be less likely. The similarity of
one virus to the others and its likely phylogenetic origin can
also be determined by comparing the genetic coding for those
parts of the viruses which are essential for its survival, and
therefore in which mutation rates would be low (Andersnn and
Gazzard, 1990:88). Using this methodology Anderson and
Gazzard (1990) found that HIV-2 may have emerged from a
simian group of viruses quite recently, but there is no
corresponding recent ancestor for HIV-l. This may imply that
HIV -1 has been present in the community for much longer
than earlier research had suggested (Anderson and Gazzard,
1990:88).
HIV replication has three steps at which mutations are
likely to occur: (1) the viral DNA polymerase lacks the error-
correcting features found in analogous cellular enzymes, (2) the
copying errors it makes in converting viral RNA into a single
DNA strand and then synthesizing the complementary strand
are not corrected, (3) the cellular RNA polymerase that makes
the genetic material for new virions also does not correct its
own errors (Haseltine and Wong-Staal, 1988:24). These three
steps are common to all retroviruses, and they have been found
to produce an average of about one mutation per replication
cycle (Haseltine and Wong-Staal, 1988:24).
Although point mutations are the most frequent source of
genetic diversity in most organisms, retroviruses are capable of
generating a whole series of additional complex genetic
changes that are of potential importance (Wain-Hobson,
1994: 199). These other changes include duplications,
deletions, substitutions with insertion, and deletions with
insertions (Wain-Hobson, 1994:199). In other organisms, the
errors are often checked and corrected, however this is not the
case in retroviruses. Retroviruses accumulate huge numbers of
variants, and HIV studies reflect the first analyses of retrovirus
evolution (Wain-Hobson, 1994:204). Also, given the large
number of individuals infected, it is only a matter of time
before new pathogenic variants of HIV emerge (Wain-Hobson,
1994:204). At this high error rate, new mv variants can also
develop during the infection of one individual(Haseltine and
Wong-Staal, 1988:24). These mutations may affect the
progress of the disease in an individual since any change in the
virus may alter its ability to cause disease. Changes in an HIV
protein may also enable the virus to evade the immune
response directed at the protein, and thus the new variant of
HIV would be favoured by natural selection (Haseltine and
Wong-Staal, 1988:24).
The AIDS epidemic is likely to a have a substantial
impact on the world demographic pattern. The disease
primarily affects young and middle-aged adults between the
ages of 20 to 49 (Brandt, 1993:550). These individuals are the
reproductively and economically active members of society. If
a substantial number of them exhibit a decrease in biological
fitness, the population structure could be affected in two ways.
First, a decrease in the total number of individuals of this
generation will affect the older generation. In the population
age pyramid of a society, the older cohorts depend on the
middle-aged cohorts for support (Smelser, 1988:345). This
support maximizes the number of individuals that have long
life expectancies. By decreasing the number of young and
middle-aged individuals, fewer old-aged individuals will have
long life spans (Brinkerhoff and White, 1988:514).
Second, the decrease in fitness of young to middle-aged
adults can result in a decrease in the general fertility rate of a
population (Smelser, 1988:347). Thus, if fewer individuals
produce offspring, a second change in population dynamics is
evident, namely a decrease in the number of young cohorts
(Smelser, 1988:347). The overall effect would be a decrease in
world total population (Brinkerhoff and White, 1988:513).
Since the concentration of mv positive individuals is
unequal in different regions of the world, the impact of the
disease would be apparent as a change in the population
mosaic. In addition, some genetic alleles are more prevalent in
certain regions of the world. By decreasing the number of
individuals with these alleles, these traits could, in effect, be
removed from the gene pool thus changing both the genotype
and phenotype frequencies observed in future generations. This
would have a direct impact on the evolution of Homo sapiens.
In 1984, when HIV was shown to be the cause of AIDS,
many researchers doubted that a cure would be found. The
reason is that HIV can hide in the cells of the central nervous
system, where it is protected by the blood-brain barrier, which
many drugs can not penetrate (Brandt, 1993:548). Even if a
drug could penetrate the barrier, brain cells already damaged by
the virus may never be repaired (Yarchoan et al., 1988:85).
At present, researchers are experimenting with several
different drugs to stop the virus from spreading in an infected
individual. To date, the only drug which is showing promising
results is azidothymidine (AZT).
Any therapeutic agent used against a pathogen, must
either kill the pathogen or stop it from multiplying, without
harming the infected host (Yarchoan et aI., 1988:85). Often the
drug used will attack a biochemical pathway unique to the
pathogen (Yarchoan et aI., 1988:85). Viruses, however,
present a more difficult problem because they are simply
packets of genetic material (RN A in HIV) protected by
glycoproteins and lipids (Yarchoan et aI., 1988:87. An RNA
virus cannot replicate on its own. Rather, it must rely on
another organisms' genetic machinery and biochemical
pathways in order to replicate (Yarchoan et aI., 1988:87).
AZT is being used to treat severely infected AIDS
patients. AZT is not a cure for AIDS, rather it prolongs the
patients' life. AZT was originally synthesized in 1964 by
Jerome P. Horwitz of the Michigan Cancer Foundation as a
potential anti-cancer drug, which failed (Yarchoan et aI.,
1988:92). However, when doctors used AZT against AIDS, it
inhibited the production of viral DNA by two mechanisms:
competitive inhibition and chain termination (Yarchoan et aI.,
1988:92). In competitive inhibition, AZT triphosphate binds
to reverse transcriptase at a site that ordinarily binds to
physiological nucleoside triphosphates (Yarchoan et aI.,
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1988:92). In chain termination, reverse transcriptase is
deceived into incorporating AZT triphosphate in a growing
chain of viral DNA in place of normal thymidine triphosphate
(Yarchoan et al., 1988:92). When the viral DNA chain tries to
add the next link, it is prevented because AZT triphosphate
lacks the hydroxyl (OH) group that is needed to copy the
chemical bond to the next link: (Yarchoan et aI., 1988:92).
AZT was first tested on an AIDS patient on July 3, 1985,
and it was shown to increase the survival time and improve the
quality of life for the patient (Yarchoan et al., 1988:87). After
taking AZT for several weeks, the patient gained weight and
had an increased number of helper T4 cells (Yarchoan et al.,
1988:96). AZT can reduce the amount of HIV present in
patients, but these improvements are only temporary and,
because of side effects that occur in some patients, some
researchers doubt whether the benefits outweigh the side effects
(Yarchoan et al., 1988:96). The main problem with AZT is its
toxicity, especially to bone marrow, such that patients on
AZT often develop anaemia (a decrease in red blood cells)
(Yarchoan et aI., 1988:97). Despite the side effects, AZT has
been shown to increase the survival time of patients with
advanced AIDS by about one year (Yarchoan et al., 1988:96).
In March of 1987, the U.S. Food and Drug
Administration approved AZT as a prescription drug for severe
HIV infected patients (Shubert, 1992:8). However, AZT
represents only the beginning to finding a cure for AIDS, and
it is hoped that with further research a vaccine will be
developed.
In the early 1980's young homosexual males were dying
of a mysterious illnesses, which should have been fought by
their own immune systems. Research into the causes of these
deaths led to the discovery of a new disease, named AIDS.
Early studies showed that the disease was passed through the
blood or by sexual intercourse. In 1983 the virus which causes
AIDS was named HIV.
HIV is an RNA retrovirus, which contains an enzyme
(reverse transcriptase) to reverse its genomic information
(RNA) to DNA, the type of genomic information found in its
host. The virus invades by attaching to the host cell and
injects its core. Enzymes change the viral RNA into DNA, and
then incorporate it into the hosts' genome. Once an individual
is infected, the number of functioning T4 cells decreases and
thus hampers the immune systems' ability to fight off
infections. The virus can remain dormant in the host for up to
10 years, and then spontaneously manifest itself as "full
blown" AIDS.
Current research has proposed three possible evolutionary
patterns for HIV all of which include its relationship to SIV.
All three theories suggest that the viruses HIV-l, HIV-2, and
SIV share a common ancestor, but the authors of these
theories disagree on the time of divergence and the order of
events. All three use different methods for determining the
phylogeny, thus further research is required to definitively
support one theory over another.
HIV has the potential to affect world population
dynamics. Since the disease is most prevalent among the
reproductively fertile members of society, it can affect that
group directly, as well cohorts both in younger and older
groups. Also, since the percentage of individuals afflicted
varies with location, the effect of the disease will be to change
the population mosaic of each society differently.
Researchers are currently studying various drugs and their
affects on HIV in the hopes of finding a cure or vaccine. To
date, the only drug which seems to be effective is AZT. AZT
inhibits the spread of HIV by halting the growth of the viral
DNA chain. Once AZT is incorporated into the chain there is
nothing the virus can do to correct it.
AZT is not a cure for AIDS, it only prolongs the
individuals life by about one year. It is hoped that through
future research an AIDS vaccine will be developed, which will
bring an end to this devastating disease.
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